AngioDynamics (ANGO) Q1 2026 Earnings Transcript

Image source: The Motley Fool.

Thursday, October 2, 2025 astatine 8:00 a.m. ET

• President and Chief Executive Officer — James Clemmer

• Executive Vice President and Chief Financial Officer — Stephen Trowbridge

Need a punctuation from a Motley Fool analyst? Email [email protected]

Operator: Good morning, and invited to the AngioDynamics Fiscal Year 2026 First Quarter Earnings Call. [Operator Instructions] As a reminder, this league telephone is being recorded. The quality merchandise detailing AngioDynamics' fiscal 2026 archetypal 4th results crossed the ligament earlier this greeting and is disposable connected the company's website. This league telephone is besides being broadcast unrecorded implicit the net astatine the Investors conception of the company's website astatine www.angiodynamics.com. A webcast replay of the telephone volition beryllium disposable astatine the aforesaid tract astir 1 hr aft the extremity of today's call.

Before we begin, I'd similar to caution listeners that during the people of this league call, the institution volition marque projections oregon forward-looking statements regarding aboriginal events, including statements astir expected revenue, adjusted net and gross margins for fiscal twelvemonth 2026, arsenic good arsenic trends that whitethorn continue. Management encourages you to reappraisal the company's past and aboriginal filings with the SEC, including, without limitation, the company's Forms 10-Q and 10-K, which place circumstantial factors that whitethorn origin existent results oregon events to disagree materially from those described successful the forward-looking statements. The institution volition besides sermon definite non-GAAP and pro forma fiscal measures during this call.

Management uses these measures to found operational goals and reappraisal operational show and believes that these measures whitethorn assistance investors successful analyzing the underlying trends successful the company's concern implicit time. Investors should see these non-GAAP and pro forma measures successful summation to, not arsenic a substitute for oregon arsenic superior to fiscal reporting with measures prepared successful accordance with GAAP. A descent bundle offering penetration into the company's fiscal results is besides disposable successful the Investors conception of the company's website nether Events and Presentations. This presumption should beryllium work successful conjunction with the property merchandise discussing the company's operating results and fiscal show during this morning's league call.

Unless different noted, each metrics and maturation rates mentioned during today's telephone are connected a pro forma basis, which excludes the results of the dialysis and BioSentry concern that were divested successful June 2023, the PICC and midline products that were divested successful February 2024 and the vigor frequence and Syntrax enactment catheter products that we discontinued successful February 2024. Also, unless different noted, each comparisons volition beryllium the archetypal fiscal 4th of 2026 versus the archetypal fiscal 4th of 2025. Now I'd similar to crook the telephone implicit to Jim Clemmer, AngioDynamics' President and Chief Executive Officer. Mr. Clemmer?